Rosen Law Firm reminds purchasers of Erasca, Inc. common stock between January 14, 2025 and April 26, 2026 of the August 10, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Erasca, along with its CEO and CFO, made false and misleading statements about its lead oncology drug candidate ERAS-0015, touting it as a potential best-in-class therapy with superior preclinical results compared to Revolution Medicines' competing drug candidate RMC-6236, while failing to disclose that those comparisons were allegedly improper, exposed Erasca to patent and trade secret disputes, and lacked a reasonable basis. Investors who purchased Erasca common stock during the class period may be entitled to compensation through a contingency fee arrangement without out-of-pocket costs. Rosen Law Firm, which has recovered hundreds of millions of dollars for investors and was ranked number one by ISS Securities Class Action Services for number of settlements in 2017, encourages investors to select qualified counsel with a track record of success.
Erasca IncSecurities class action lawsuit alleging false statements about drug candidate ERAS-0015 and improper comparisons to competitor's drug.
Revolution Medicines IncMentioned as comparator in lawsuit; Erasca's alleged improper comparisons to Revolution Medicines' drug candidate RMC-6236.